Dáil Éireann Debate, Tuesday - 13 June 2023
1203. Deputy Peadar Tóibín asked the Minister for Health further to Parliamentary Question No. 590 of 24 January 2023, if any price agreement has been reached between the HSE and a drug company (details supplied) for Sunosi in the treatment of narcolepsy or obstructive sleep apnoea; if so, if he will provide an update and indicate a timeframe when the drug will be available in Ireland; and if he will make a statement on the matter. [27844/23]
Amharc ar fhreagraThe Health Service Executive (HSE) has statutory responsibility for decisions on pricing and reimbursement of medicines under the community drug schemes, in accordance with the Health (Pricing and Supply of Medical Goods) Act 2013.
In October 2022, the HSE approved the drug Sunosi® (solriamfetol) for reimbursement under High Tech Arrangements subject to managed access for adult patients with narcolepsy (with or without cataplexy), in accordance with the proposed place in therapy as a second-line treatment.
However, the company that holds the marketing authorisation for Sunosi® (solriamfetol) has not yet launched the product in Ireland.
